Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib
Arch Bronconeumol. 2023 Jul;59(7):464-466.
doi: 10.1016/j.arbres.2023.02.010.
Epub 2023 Feb 27.
[Article in
English,
Spanish]
Authors
Michele Mondoni
1
, Francesco Varone
2
, Fausta Alfano
3
, Giuseppe Muscato
4
, Caterina Conti
5
, Laura Saderi
6
, Bruno Iovene
2
, Fabiano Di Marco
7
, Carlo Vancheri
4
, Luca Richeldi
2
, Stefano Centanni
3
, Giovanni Sotgiu
6
Affiliations
- 1 Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Italy. Electronic address: michele.mondoni@asst-santipaolocarlo.it.
- 2 Division of Pulmonary Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- 3 Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, Università degli Studi di Milano, Italy.
- 4 Department of Clinical and Experimental Medicine, Regional Referral Centre for Rare Lung Disease, A.O.U. Policlinico-San Marco, University of Catania, Italy.
- 5 Respiratory Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
- 6 Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
- 7 Respiratory Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; Department of Health Sciences, Università degli Studi di Milano, Italy.
No abstract available
MeSH terms
-
Humans
-
Idiopathic Pulmonary Fibrosis* / drug therapy
-
Indoles / therapeutic use
-
Treatment Outcome
-
Vital Capacity